Fujifilm pumps $111m into its US biologics and stem cell network

URLhttps://bioprocessintl.com/bioprocess-insider/faci
SourceBioProcess International
Date Published01/08/2019
Author NameDan Stanton
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Fujifilm Cellular Dynamics Inc. (FCDI)
Parent companyFujifilm Corporation
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Year reshoring announced:2019
Year reshoring implemented or to be implemented:2020
Capital investment ($):21
Country(ies) from which reshored:Japan
City reshored to:Madison
State(s) reshored to:WI
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredstem cells
What domestic positive factors made reshoring more attractive?Automation/technology, Customer responsiveness improvement, Customization/Flexibility, Eco-system synergies
Find Reshoring Articles